ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
03 nov. 2023 14h00 HE
|
ImCheck Therapeutics SAS
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 Interim data from EVICTION-2 study confirms safety and tolerability...
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
30 oct. 2023 06h41 HE
|
ImCheck Therapeutics SAS
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting Marseille, France, October 30, 2023 – ImCheck...
ImCheck Appoints Thomas Civik as Independent Chairman of the Board
23 mars 2023 03h00 HE
|
ImCheck Therapeutics SAS
ImCheck Appoints Thomas Civik as Independent Chairman of the Board Marseille, France, March 23, 2023 – ImCheck Therapeutics announced today the appointment of Thomas Civik as independent...
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
14 mars 2023 17h30 HE
|
ImCheck Therapeutics SAS
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR Marseille, France, March 14, 2023 – ImCheck Therapeutics...
Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022
10 sept. 2022 09h15 HE
|
ImCheck Therapeutics SAS
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more checkpoint-inhibitor regimen, across a range of ICT01 doses in...
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
08 avr. 2022 13h00 HE
|
ImCheck Therapeutics SAS
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Datafrom the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022 Continued positive safety data across a range of ICT01 doses...
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
03 févr. 2022 05h03 HE
|
ImCheck Therapeutics SAS
ImCheck Announces First Patients Dosedin Phase II of EVICTION Trial for ICT01 EVICTION trial proceeds to Phase IIa based on promising Phase I patient datafor ICT01 across a broad range of...
ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference
06 janv. 2022 06h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference Marseille, France, January 6, 2022 – ImCheck Therapeutics announced today that its Chief Executive Officer, Pierre...
ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine
20 oct. 2021 14h21 HE
|
ImCheck Therapeutics SAS
ImCheck Publishes Comprehensive Overview of the DevelopmentResults of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cellsin Science Translational Medicine ...
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021
01 oct. 2021 08h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021 Marseille, France, October 1, 2021 – ImCheck Therapeutics today...